glp 1 drugs for prediabetes GLP-1 Costs Explained: Managing Coverage Challenges GLP-1 | Summary
Description
doi: 10.3389/fendo.2024.1330936 Received 31 October 2023 Accepted 02 January 2024 Published 06 February 2024 Volume 15 - 2024 Edited by Julianne Hall, Quinnipiac University, United States Reviewed by Eric Morris Bomberg, University of Minnesota, United States Michihiro Takahashi, Takahashi Psychiatric Clinic, Japan Updates Copyright 2024 Chen, Cai, Zou and Fu
In addition, risks associated with hypoglycemia are minimal and usually only occur in combination therapy with insulin secretagogues or insulin
These treatments are not appropriate for all patients and may be contraindicated in individuals with certain medical conditions including hormone-sensitive cancers, blood clotting disorders, severe liver disease, or cardiovascular conditions
Pol J Pharmacol
Eur Clin Respir J
The thyroid cancer debate has been one of the most significant GLP-1 RA-associated safety concerns
